KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Retained Earnings (2016 - 2025)

TherapeuticsMD's Retained Earnings history spans 16 years, with the latest figure at -$952.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings changed 0.06% year-over-year to -$952.4 million; the TTM value through Dec 2025 reached -$952.4 million, changed 0.06%, while the annual FY2025 figure was -$952.4 million, 0.06% changed from the prior year.
  • Retained Earnings reached -$952.4 million in Q4 2025 per TXMD's latest filing, roughly flat from -$951.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$918.3 million in Q1 2021 to a low of -$1.1 billion in Q1 2022.
  • Average Retained Earnings over 5 years is -$969.3 million, with a median of -$951.9 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: decreased 22.07% in 2021, then increased 14.31% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$1.1 billion in 2021, then increased by 10.65% to -$939.4 million in 2022, then fell by 1.09% to -$949.6 million in 2023, then dropped by 0.23% to -$951.8 million in 2024, then dropped by 0.06% to -$952.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Retained Earnings are -$952.4 million (Q4 2025), -$951.8 million (Q3 2025), and -$951.9 million (Q2 2025).